PhaseBio Pharmaceuticals Inc
PHASDelisted Dec 21, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001169245
PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by PhaseBio Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for PhaseBio Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Harrigan Edmund | Director | 9,750 | May 19, 2023 | 0 |
| Loewy Caroline M | Director | 3,750 | May 19, 2023 | 0 |
| Hutson Nancy J | Director | 37,510 | May 19, 2023 | 0 |
| van den Broek Richard | Director | 0 | May 19, 2023 | 0 |
| Thorp Clay | Director | 36,693 | May 19, 2023 | 0 |
| Humphries William D. | Director | 2,538 | May 19, 2023 | 0 |
| Sapir Alex | Director | 3,750 | May 19, 2023 | 0 |
| Kerins Patrick J | 10% Owner | 4,857,525 | Oct 26, 2022 | 0 |
| Sandell Scott D | 10% Owner | 4,857,525 | Oct 26, 2022 | 0 |
| Baskett Forest | 10% Owner | 4,857,525 | Oct 26, 2022 | 0 |
| New Enterprise Associates 13 LP | 10% Owner | 4,857,525 | Oct 26, 2022 | 0 |
| NEA 13 GP, Ltd | 10% Owner | 4,857,525 | Oct 26, 2022 | 0 |
| NEA Partners 13, Limited Partnership | 10% Owner | 4,857,525 | Oct 26, 2022 | 0 |
| Mow Jonathan P | Chief Executive Officer | 132,502 | May 24, 2022 | 0 |
| Sharp John P | Chief Financial Officer | 65,767 | May 24, 2022 | 0 |
| Arnold Susan Elizabeth | SVP, Technical Operations | 41,236 | May 24, 2022 | 0 |
| Hanson Kristopher | SVP and General Counsel | 8,463 | May 24, 2022 | 0 |
| Burkhardt Glen | SVP of Human Resources | 0 | May 24, 2022 | 0 |
| Birchall Jonathan | Chief Commercial Officer | 20,000 | May 24, 2022 | 0 |
| Lee John Sang | Chief Medical Officer | – | Feb 28, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 2022 (view filing)4:41 PM ET | Oct 25 | 1 day | Kerins Patrick J and 5 others10% Owner | SSale | −1.78M | $0.147 | −$262.3K | −26.9%4.86M after | |
| May 24, 2022 (view filing) | May 23 | 1 day | Burkhardt GlenSVP of Human Resources | SSale | −11.2K | $0.79 | −$8.89K | −100.0%0 after | |
| May 20, 2022 (view filing) | Aug 18, 2021 | 275 days | Hutson Nancy JDirector | PPurchase | +3.00K | $3.08 | +$9.24K | +300.0%4.00K after | Amended |
| Nov 23, 2021 (view filing) | Nov 19 | 4 days | Burkhardt GlenVP, Human Resources | SSale | −5.77K | $2.37 | −$13.7K | −100.0%0 after | |
| Aug 18, 2021 (view filing) | Aug 18 | Same day | Thorp ClayDirector | PPurchase | +10.0K | $3.00 | +$30.0K | +43.6%32.9K after |